| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
The primary targets of Trametenolic acid are not fully defined, but it is known to have multiple biological activities. It has anti-inflammatory effects by modulating cytokine production and inhibiting inflammatory pathways. It also has anti-tumor effects by inducing apoptosis and inhibiting cell proliferation in cancer cells. Trametenolic acid has immunomodulatory effects and may enhance immune function.
|
|---|---|
| ln Vitro |
By triggering the ERK1/2 signaling pathway, trametenolic acid (1 mg/mL; 15–30 minutes) causes the overexpression of autophagy-related proteins (Beclin-1, Atg12, and LC3) in B16-F1 cells [1]. Through a twofold synergistic mechanism, trimethenoic acid (1 mg/mL; 24 hours; B16-F1 cells) has antimelanogenic actions [1]. Melanin synthesis was boosted by roughly 20% and 40% in cells transfected with siRNA against mTOR and Atg5, respectively, by trimethenoic acid (0.1-4 mg/mL; 52 hours; B16-F1 cells) [1].
In vitro, trametenolic acid has been shown to have anti-inflammatory, anti-tumor, and immunomodulatory activities. It inhibits the production of inflammatory cytokines and reduces oxidative stress in various cell types. In cancer cell lines, trametenolic acid induces apoptosis and inhibits cell proliferation. |
| ln Vivo |
In vivo, trametenolic acid has been studied for its potential therapeutic applications. It has been shown to have anti-tumor effects in animal models of cancer. It also has immunomodulatory effects and may enhance immune function. However, specific in vivo efficacy data are limited.
|
| Enzyme Assay |
In vitro enzyme or receptor binding assays for trametenolic acid are not typically performed, as it does not have a single specific target. Its anti-inflammatory activity can be assessed by measuring the production of inflammatory cytokines in immune cells. Its anti-tumor activity can be assessed by measuring cell viability and apoptosis in cancer cell lines.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: B16-F1 Cell Tested Concentrations: 1 mg/mL Incubation Duration: 15 and 30 minutes Experimental Results: Increased expression levels of phosphorylated p38, phosphorylated ERK1/2, Beclin-1, Atg12 and LC3 respectively About 46%, 10%, 48%, 126% and 49%. Western Blot Analysis[1] Cell Types: B16-F1 Cell Tested Concentrations: 1 mg/mL Incubation Duration: 24 hrs (hours) Experimental Results: Increased expression of ERK1/2 and p-ERK1/2, diminished MITF, tyrosinase and TRP 1 levels. In vitro cell-based assays for trametenolic acid are performed using various cell lines, including cancer cells and immune cells. Cells are treated with the compound, and cell viability, proliferation, and apoptosis are assessed using standard assays. The production of inflammatory cytokines is measured by ELISA. |
| Animal Protocol |
In vivo animal experiments for trametenolic acid are conducted using rodent models of cancer and inflammation. The compound is administered orally or intraperitoneally. Tumor growth is measured in xenograft models. Inflammatory markers are assessed in models of inflammation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of trametenolic acid indicate that it has a molecular weight of 456.70 and a molecular formula of C30H48O3. It is a triterpenoid compound. The compound is typically stored under appropriate conditions for research use. Its anti-inflammatory, anti-tumor, and immunomodulatory properties have been characterized.
|
| Toxicity/Toxicokinetics |
Toxicology (toxicology) data for trametenolic acid are limited. As a natural compound, it is generally considered safe at moderate doses. However, its safety profile in the context of therapeutic use requires further evaluation. The compound is for research use only and not for human therapeutic use.
|
| References | |
| Additional Infomation |
Aztracinic acid B is a triterpenoid compound. It has been reported to be present in Azotobacter, Schizophyllum commune, and other organisms with relevant data.
Other information: Trametenolic acid is a triterpenoid found in medicinal mushrooms. It has anti-inflammatory, anti-tumor, and immunomodulatory properties. Its CAS number is 24160-36-9. |
| Molecular Formula |
C30H48O3
|
|---|---|
| Molecular Weight |
456.71
|
| Exact Mass |
456.36
|
| CAS # |
24160-36-9
|
| PubChem CID |
12309443
|
| Appearance |
White to off-white solid powder
|
| Density |
1.07±0.1 g/cm3
|
| Melting Point |
259-261 ºC
|
| Vapour Pressure |
3.26E-15mmHg at 25°C
|
| LogP |
7.543
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
33
|
| Complexity |
862
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
CC(=CCC[C@H]([C@H]1CC[C@@]2([C@@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C)C(=O)O)C
|
| InChi Key |
NBSBUIQBEPROBM-GIICLEHTSA-N
|
| InChi Code |
InChI=1S/C30H48O3/c1-19(2)9-8-10-20(26(32)33)21-13-17-30(7)23-11-12-24-27(3,4)25(31)15-16-28(24,5)22(23)14-18-29(21,30)6/h9,20-21,24-25,31H,8,10-18H2,1-7H3,(H,32,33)/t20-,21-,24+,25+,28-,29-,30+/m1/s1
|
| Chemical Name |
(2R)-2-[(3S,5R,10S,13R,14R,17R)-3-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methylhept-5-enoic acid
|
| Synonyms |
(+)-trametenolic acid B Trametenolic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~109.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.47 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1896 mL | 10.9479 mL | 21.8957 mL | |
| 5 mM | 0.4379 mL | 2.1896 mL | 4.3791 mL | |
| 10 mM | 0.2190 mL | 1.0948 mL | 2.1896 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
